2- (4'- (methylamino)phenyl)- 6- hydroxybenzothiazole (Pittsburgh compound B)

an amyloid imaging agent; structure in first source

Also Known As:

Pittsburgh compound B; ((11)C)PIB; (11C)6-OH-BTA-1; 11C-PIB; 6-OH-BTA-1; N-methyl-(11C)2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazole; N-methyl-2-(4'-methylaminophenyl)-6-hydroxybenzothiazole; PIB benzothiazole

Networked: 482 relevant articles (8 outcomes, 99 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Jack, Clifford R: 37 articles (01/2022 - 05/2010)
2.	Klunk, William E: 34 articles (01/2022 - 06/2003)
3.	Mathis, Chester A: 32 articles (01/2022 - 06/2003)
4.	Petersen, Ronald C: 28 articles (11/2021 - 08/2010)
5.	Lowe, Val J: 25 articles (01/2022 - 05/2012)
6.	Villemagne, Victor L: 25 articles (01/2022 - 04/2007)
7.	Senjem, Matthew L: 24 articles (01/2022 - 05/2012)
8.	Knopman, David S: 21 articles (11/2021 - 06/2012)
9.	Kantarci, Kejal: 19 articles (01/2022 - 05/2012)
10.	Rowe, Christopher C: 19 articles (11/2017 - 04/2007)

Related Diseases

1.	Alzheimer Disease (Alzheimer's Disease) 02/14/2013 - "When 11C-PiB is used as a treatment endpoint in intervention studies for Alzheimer's disease (AD), a concern is whether the clearance of the tracer changes from one scan to the next, increasing within subject variability in the PET signal. " 05/01/2022 - "Five cognitively healthy controls and five patients with Alzheimer disease were assessed using [18 F]FDG and [11 C]PiB PET to validate the findings from the phantom study. " 05/01/2022 - "The present study aimed to define the optimal β value in BPL required to diagnose Alzheimer disease from brain positron emission tomography (PET) images acquired using 18 F-fluoro-2-deoxy-D-glucose ([18 F]FDG) and 11 C-labeled Pittsburg compound B ([11 C]PiB). " 09/29/2020 - "We examined 166 subjects who underwent a [11C] Pittsburgh compound-B PET scan through the Japanese Alzheimer's Disease Neuroimaging Initiative (J-ADNI) study. " 01/01/2018 - "The aim of this study was to identify the brain networks from early-phase 11C-PIB (perfusion PIB, pPIB) data and to compare the brain networks of patients with differentiating Alzheimer's disease (AD) with cognitively normal subjects (CN) and of mild cognitively impaired patients (MCI) with CN. "
2.	Dementia (Dementias) 01/01/2020 - "To our knowledge, the present study is the first measuring CT in eyes from MCI and dementia eyes positive to 11C-PiB PET/CT reporting a significant trend towards CT thinning in MCI patients which became more pronounced in dementia stage. " 01/01/2018 - "This observational study examined 60 elderly volunteers without dementia (mean age at baseline 55.4 and at follow-up 70.9 years, 55.5% women) from the Finnish population-based, nationwide Health2000 study with [11C]Pittsburgh compound B-PET imaging in 2014-2016. " 04/09/2013 - "A total of 194 participants (mean age 85.5 years, range 82-95) who completed the Ginkgo Evaluation of Memory Study (GEMS) and remained dementia-free subsequently completed Pittsburgh compound B-PET imaging. " 02/01/2009 - "White matter kinetics were also characterized in vivo through 11C-PiB PET studies in 27 HCs and 34 patients with dementia. " 10/01/2023 - "Patients experiencing an ICH without overt dementia were prospectively recruited (n = 68) for brain MRI and Pittsburgh compound B (PiB) positron emission tomography scans at baseline. "
3.	Amyloid Plaque 10/24/2019 - "Here, we demonstrate this technique on the example of production of a PET tracer Pittsburgh compound B ([11C]PiB), a gold standard in vivo imaging agent for amyloid plaques in the human brains." 06/01/2009 - "The aim of the study was to determine the association between cerebral amyloid plaque load, as measured by means of the positron emission tomography (PET) tracer carbon-11-labeled Pittsburgh Compound B ([11C]PiB) and CSF Abeta42 in AD. " 01/01/2021 - "Positron emission tomography (PET) with Pittsburgh Compound-B (PiB) detects fibrillar Aβ pathology in living people with DS and AD, but its relationship with heterogeneous Aβ forms aggregated within amyloid deposits is not well understood. " 11/01/2019 - "In addition, certain models of [11 C]-PIB delivery reflect cerebral blood flow rather than amyloid plaques. " 01/01/2018 - "We developed Mn0.6Zn0.4Fe2O4 (MZF) modified by Pittsburgh compound B (PiB) to specifically bind to amyloid plaques. "
4.	Cognitive Dysfunction 10/01/2019 - "The current study investigates the magnitude of 11C-PiB PET signal in the lateral ventricles of an independent group of Alzheimer and mild cognitive impairment subjects. " 11/15/2008 - "Previous studies have shown an overlap in (11)C PiB PET retention between AD, mild cognitive impairment (MCI) patients and normal elderly control (NC) participants. " 01/01/2022 - "There was an association of DTI(FA) and DTI(AD) with cognition and psychomotor speed for progressive MS, and of 11C-PIB uptake and MTR for relapsing-remitting MS. MTR in the Thalamus (β= -0.51, p = 0.021) and Corpus Callosum (β= -0.24, p = 0.033) were predictive of cognitive impairment. " 01/01/2022 - "Different neuroimaging methods have been used to quantify myelin and relate it to cognitive dysfunctions, among them Magnetization Transfer Ratio (MTR), Diffusion Tensor Imaging (DTI), and, more recently, Positron Emission Tomography (PET) with 11C-PIB. " 01/01/2021 - "However, neither striatal nor cortical 11C-PiB retention was related to cognitive decline. "
5.	Parkinson Disease (Parkinson's Disease) 01/01/2008 - "[(11)C]-PIB imaging in patients with Parkinson's disease: preliminary results." 12/01/2010 - "[(11)C]PIB-, [(18)F]FDG-PET and MRI imaging in patients with Parkinson's disease with and without dementia." 05/01/2010 - "Findings of increased Pittsburgh Compound B (PiB) binding in subjects with Lewy Body Disease (LBD) compared with Parkinson's disease and dementia (PDD) may explain phenotype differences in the spectrum of Dementia with Lewy Bodies (DLB), and show promise in guiding future therapeutic trials aimed at this disease. " 01/05/2010 - "[(11)C]-Pittsburgh Compound B (PIB) PET is specific for fibrillar Abeta molecular pathology but not for pathologic diagnosis of comorbid Alzheimer disease in individuals with Parkinson disease dementia. " 12/01/2019 - "Clinical amyloid-β imaging using Pittsburgh Compound B (PiB) supports neuropathological studies which found that amyloid-β pathology is more common in dementia with Lewy bodies than in Parkinson's disease dementia. "

Related Drugs and Biologics

1.	Amyloid (Amyloid Fibrils)
2.	2- (4'- (methylamino)phenyl)- 6- hydroxybenzothiazole (Pittsburgh compound B)
3.	Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)
4.	Carbon
5.	Carbon-11
6.	Monoclonal Antibodies
7.	Peptides (Polypeptides)
8.	Radioisotopes (Radionuclides)
9.	Biomarkers (Surrogate Marker)
10.	flutemetamol

Related Therapies and Procedures

1.	Therapeutics
2.	Denervation